HOXA9 Regulome and Pharmacological Interventions in Leukemia

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2024 Jul 17

PMID 39017854

Authors

Sajesan Aryal

Rui Lu

Affiliations

Soon will be listed here.

Abstract

HOXA9, an important transcription factor (TF) in hematopoiesis, is aberrantly expressed in numerous cases of both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is a strong indicator of poor prognosis in patients. HOXA9 is a proto-oncogene which is both sufficient and necessary for leukemia transformation. HOXA9 expression in leukemia correlates with patient survival outcomes and response to therapy. Chromosomal transformations (such as NUP98-HOXA9), mutations, epigenetic dysregulation (e.g., MLL- MENIN -LEDGF complex or DOT1L/KMT4), transcription factors (such as USF1/USF2), and noncoding RNA (such as HOTTIP and HOTAIR) regulate HOXA9 mRNA and protein during leukemia. HOXA9 regulates survival, self-renewal, and progenitor cell cycle through several of its downstream target TFs including LMO2, antiapoptotic BCL2, SOX4, and receptor tyrosine kinase FLT3 and STAT5. This dynamic and multilayered HOXA9 regulome provides new therapeutic opportunities, including inhibitors targeting DOT1L/KMT4, MENIN, NPM1, and ENL proteins. Recent findings also suggest that HOXA9 maintains leukemia by actively repressing myeloid differentiation genes. This chapter summarizes the recent advances understanding biochemical mechanisms underlying HOXA9-mediated leukemogenesis, the clinical significance of its abnormal expression, and pharmacological approaches to treat HOXA9-driven leukemia.

References

de Bruijn M, Speck N, Peeters M, Dzierzak E . Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. EMBO J. 2000; 19(11):2465-74. PMC: 212758. DOI: 10.1093/emboj/19.11.2465. View

Canu G, Athanasiadis E, Grandy R, Garcia-Bernardo J, Strzelecka P, Vallier L . Analysis of endothelial-to-haematopoietic transition at the single cell level identifies cell cycle regulation as a driver of differentiation. Genome Biol. 2020; 21(1):157. PMC: 7329542. DOI: 10.1186/s13059-020-02058-4. View

Belyavsky A, Petinati N, Drize N . Hematopoiesis during Ontogenesis, Adult Life, and Aging. Int J Mol Sci. 2021; 22(17). PMC: 8430730. DOI: 10.3390/ijms22179231. View

Zovein A, Hofmann J, Lynch M, French W, Turlo K, Yang Y . Fate tracing reveals the endothelial origin of hematopoietic stem cells. Cell Stem Cell. 2008; 3(6):625-36. PMC: 2631552. DOI: 10.1016/j.stem.2008.09.018. View

Seita J, Weissman I . Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010; 2(6):640-53. PMC: 2950323. DOI: 10.1002/wsbm.86. View

Cheng H, Zheng Z, Cheng T . New paradigms on hematopoietic stem cell differentiation. Protein Cell. 2019; 11(1):34-44. PMC: 6949320. DOI: 10.1007/s13238-019-0633-0. View

Kim C . Homeostatic and pathogenic extramedullary hematopoiesis. J Blood Med. 2012; 1:13-9. PMC: 3262334. DOI: 10.2147/JBM.S7224. View

Zhang C, Lodish H . Cytokines regulating hematopoietic stem cell function. Curr Opin Hematol. 2008; 15(4):307-11. PMC: 2677548. DOI: 10.1097/MOH.0b013e3283007db5. View

Franco R . Measurement of red cell lifespan and aging. Transfus Med Hemother. 2013; 39(5):302-7. PMC: 3678251. DOI: 10.1159/000342232. View

10.

Seifert A, Werheid D, Knapp S, Tobiasch E . Role of Hox genes in stem cell differentiation. World J Stem Cells. 2015; 7(3):583-95. PMC: 4404393. DOI: 10.4252/wjsc.v7.i3.583. View

11.

Luo Z, Rhie S, Farnham P . The Enigmatic HOX Genes: Can We Crack Their Code?. Cancers (Basel). 2019; 11(3). PMC: 6468460. DOI: 10.3390/cancers11030323. View

12.

Bach C, Buhl S, Mueller D, Garcia-Cuellar M, Maethner E, Slany R . Leukemogenic transformation by HOXA cluster genes. Blood. 2010; 115(14):2910-8. DOI: 10.1182/blood-2009-04-216606. View

13.

Mark M, Rijli F, Chambon P . Homeobox genes in embryogenesis and pathogenesis. Pediatr Res. 1997; 42(4):421-9. DOI: 10.1203/00006450-199710000-00001. View

14.

Grier D, Thompson A, Kwasniewska A, McGonigle G, Halliday H, Lappin T . The pathophysiology of HOX genes and their role in cancer. J Pathol. 2005; 205(2):154-71. DOI: 10.1002/path.1710. View

15.

Slany R . The molecular biology of mixed lineage leukemia. Haematologica. 2009; 94(7):984-93. PMC: 2704309. DOI: 10.3324/haematol.2008.002436. View

16.

Damante G, Pellizzari L, Esposito G, Fogolari F, Viglino P, Fabbro D . A molecular code dictates sequence-specific DNA recognition by homeodomains. EMBO J. 1996; 15(18):4992-5000. PMC: 452237. View

17.

Collins C, Hess J . Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Oncogene. 2015; 35(9):1090-8. PMC: 4666810. DOI: 10.1038/onc.2015.174. View

18.

Banerjee-Basu S, Sink D, Baxevanis A . The Homeodomain Resource: sequences, structures, DNA binding sites and genomic information. Nucleic Acids Res. 2000; 29(1):291-3. PMC: 29851. DOI: 10.1093/nar/29.1.291. View

19.

Joshi R, Passner J, Rohs R, Jain R, Sosinsky A, Crickmore M . Functional specificity of a Hox protein mediated by the recognition of minor groove structure. Cell. 2007; 131(3):530-43. PMC: 2709780. DOI: 10.1016/j.cell.2007.09.024. View

20.

Breitinger C, Maethner E, Garcia-Cuellar M, Slany R . The homeodomain region controls the phenotype of HOX-induced murine leukemia. Blood. 2012; 120(19):4018-27. DOI: 10.1182/blood-2011-10-384685. View